Talphera
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 15
- Market Cap
- $16.4M
- Introduction
Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.
Nafamostat Efficacy in Phase 3 Registrational CRRT Study
- Conditions
- Interventions
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 166
- Registration Number
- NCT06150742
- Locations
- 🇺🇸
Wake Forest, Winston-Salem, North Carolina, United States
Study to Evaluate the Overall Performance of the Zalviso Systemâ„¢ (Sufentanil Sublingual Tablet System) 15 mcg
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 320
- Registration Number
- NCT02662764
- Locations
- 🇺🇸
Arizona Research Center, Phoenix, Arizona, United States
🇺🇸Gulfcoast Research Associates, Sarasota, Florida, United States
🇺🇸Southeastern Center for Clinical Trials, Decatur, Georgia, United States
A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain
- Conditions
- Interventions
- First Posted Date
- 2016-01-25
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 140
- Registration Number
- NCT02662556
- Locations
- 🇺🇸
HD Research, Houston, Texas, United States
🇺🇸Research Concepts, Houston, Texas, United States
Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain
- Conditions
- Interventions
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 76
- Registration Number
- NCT02447848
- Locations
- 🇺🇸
Hermann Memorial Medical Center, Houston, Texas, United States
🇺🇸Ben Taub General Hospital, Houston, Texas, United States
🇺🇸Hennepin County Medical Center, Minneapolis, Minnesota, United States
A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery
- Conditions
- Interventions
- First Posted Date
- 2015-02-05
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 161
- Registration Number
- NCT02356588
- Locations
- 🇺🇸
Shoals Medical Trials, Inc, Sheffield, Alabama, United States
🇺🇸Lotus Clinical Research, Pasadena, California, United States
🇺🇸Victory Medical Center, Houston, Texas, United States
Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects
- Conditions
- First Posted Date
- 2014-03-10
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 40
- Registration Number
- NCT02082236
- Locations
- 🇺🇸
PRA, Lenexa, Kansas, United States
Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab
- Conditions
- Interventions
- First Posted Date
- 2013-01-07
- Last Posted Date
- 2015-10-01
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 40
- Registration Number
- NCT01761565
- Locations
- 🇺🇸
PRA, Lenexa, Kansas, United States
Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics
- Conditions
- Interventions
- First Posted Date
- 2012-11-04
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 19
- Registration Number
- NCT01721070
- Locations
- 🇺🇸
PRA, Lenexa, Kansas, United States
Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy
- Conditions
- Interventions
- First Posted Date
- 2012-10-19
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 101
- Registration Number
- NCT01710345
- Locations
- 🇺🇸
Lotus Clinical Research, Pasadena, California, United States
🇺🇸Jean Brown Research, Salt Lake City, Utah, United States
Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery
- Conditions
- Interventions
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Talphera, Inc
- Target Recruit Count
- 419
- Registration Number
- NCT01660763
- Locations
- 🇺🇸
Deidre Stonestreet, Damascus, Maryland, United States